Keywords: stem cell mobilization; tumor cytoreduction; breast cancer; cyclophosphamide; etoposide; paclitaxel Metastatic carcinoma of the breast is a fatal malignancy with a median survival of about 2 years when treated with chemo-hormonal therapy. High-dose chemotherapy with autologous peripheral blood stem cell transplantation (HDC/PBSCT) has been performed increasingly over the past decade in an effort to impact positively on the usually dismal outcome of metastatic breast cancer. Unfortunately, there is a dearth of multicenter controlled trials comparing HDC/PBSCT to conventional chemotherapy. However, one single institution study revealed a survival advantage in patients treated with HDC/PBSCT 1 whereas a recent multiinstitutional trial failed to demonstrate any such benefit.
Metastatic carcinoma of the breast is a fatal malignancy with a median survival of about 2 years when treated with chemo-hormonal therapy. High-dose chemotherapy with autologous peripheral blood stem cell transplantation (HDC/PBSCT) has been performed increasingly over the past decade in an effort to impact positively on the usually dismal outcome of metastatic breast cancer. Unfortunately, there is a dearth of multicenter controlled trials comparing HDC/PBSCT to conventional chemotherapy. However, one single institution study revealed a survival advantage in patients treated with HDC/PBSCT 1 whereas a recent multiinstitutional trial failed to demonstrate any such benefit. 2 In addition, a recent multi-institutional analysis of North American patients undergoing autotransplantation for metastatic breast cancer demonstrated a 4-year progression-free survival of 32% among patients who had achieved complete response to conventional chemotherapy given prior to HDC/PBSCT. The progression-free survival was 13% among partial responders, and only 7% among nonresponders. 3 Therefore, this suggests that one should attempt to induce a complete remission prior to HDC/PBSCT. An ideal regimen for this purpose should not only be highly active against breast cancer but should also be capable of mobilizing peripheral blood stem cells (PBSC) for harvesting. The current study analyzes the results of an intense chemotherapy regimen consisting of paclitaxel, etoposide and cyclophosphamide (TEC) administered to 100 consecutive women with metastatic breast cancer who were being considered for HDC/PBSCT. The aim of this study was to determine the stem cell mobilizing ability, anti-tumor effect, and toxicity of TEC in patients with metastatic breast cancer.
Patients and methods

Patients
Patients with metastatic carcinoma of the breast were referred to the University of Connecticut Health Center, Farmington, CT, for HDC/PBSCT. Every individual was required to give informed consent prior to the administration of stem cell mobilizing chemotherapy and granulocyte colony-stimulating factor (G-CSF), and collection of PBSC. Between March 1994 and June 1997, 100 consecutive patients with metastatic breast cancer received a novel chemotherapy regimen with the aim of collecting PBSC. The protocol was approved by the institutional review board of the University of Connecticut Health Center. Eligibility criteria included an age р65 years, an ECOG performance score of 0, 1, 2 or 3, an absolute neutrophil count (ANC) у1.5 ϫ 10 9 /l, a platelet count у100 ϫ 10 9 /l, hepatic transaminases less than twice normal, a creatinine clearance у60 ml/min, a left ventricular ejection fraction у50%, and a diffusion lung capacity у50% of the predicted value.
Chemotherapy
Patients received combination chemotherapy supported by G-CSF to facilitate PBSC mobilization and harvesting as well as to optimize tumor cytoreduction. The regimen consisted of etoposide 60 mg/kg by continuous i.v. infusion from hours 0 to 18, cyclophosphamide 1.5 g/m 2 i.v. from hours 24 to 25 and 30 to 31, and paclitaxel 200 mg/m 2 i.v. from hour 48 to 51. Granulocyte colony-stimulating factor 5-10 g/kg/day i.v. was initiated from hour 60 and continued until an ANC of greater than 5 ϫ 10 9 /l was reached or until completion of PBSC collection (Table 1 ). All patients were hospitalized from hour 0 until completion of the first dose of G-CSF (3 days).
High-dose chemotherapy began 1 month after the initiation of the final cycle of TEC and consisted of busulfan 4 mg/kg/day orally for 4 days (day −10 to day −7), thiotepa 125-175 mg/m 2 /day i.v. for 4 days (day −6 to day −3), and carboplatin 200-250 mg/m 2 /day i.v. for 4 days (day −6 to day −3). Stem cells were infused on day 0. Granulocyte colony-stimulating factor 5 g/kg/day was administered i.v. from day +1 until recovery of the neutrophil count following aplasia.
Supportive care
Supportive measures during the administration of chemotherapy included an intensive anti-emetic regimen consisting of dexamethasone 10 mg i.v. 30 min prior to the initiation of etoposide and then 4 mg i.v. every 6 h until hour 60; lorazepam 0.5-1.0 mg i.v. every 6 h along with Antibiotic prophylaxis consisted of ciprofloxacin 500 mg orally twice daily from day 4 until recovery of the white blood cell (WBC) count (ANC Ͼ1 ϫ 10 9 /l) or fever requiring the initiation of parenteral antibiotics. Prophylaxis against gram-positive organisms was provided by either ampicillin 250 mg orally four times daily starting at day 6 or clarithromycin 250 mg orally twice daily from day 6 until recovery of the WBC count or initiation of parenteral antibiotics for fever. Neutropenic fever was treated with hospitalization and broad-spectrum antibiotic therapy. Other supportive measures included ranitidine 150 mg orally twice daily from day 4 until recovery of the WBC count and prednisone 40 mg orally twice daily from day 8 until recovery of the WBC count. Packed red blood cell (PRBC) transfusions were administered when the hemoglobin was р8 g/dl and platelet products were transfused for a platelet count р20 ϫ 10 9 /l. All individuals were seen in the outpatient clinic on alternate days from day 6 until recovery of the WBC count.
Peripheral blood stem cell collection
Peripheral blood stem cells were enumerated by determining the percentage of CD34-positive mononuclear cells on the day that the total WBC count exceeded 1 ϫ 10 9 /l following the nadir from chemotherapy. If the circulating CD34-positive cell count was greater than 1%, stem cell leukapheresis was conducted with a continuous flow cell separator (Cobe Spectra, Cobe CBT, Lakewood, CO, USA) processing 10-20 l of blood per day at flow rates of 50-80 ml/min. Stem cell leukapheresis was attempted following both the first as well as the second cycle of TEC in the initial group of patients. However, if an adequate number of stem cells was collected after the second cycle of TEC, any stem cells collected and cryopreserved following the first course were not utilized for PBSCT for fear of a greater likelihood of contamination with tumor cells. From December 1994 onwards, 10 ml of bone marrow obtained prior to the initiation of TEC, and 10 ml of the PBSC product collected on the first day of leukapheresis following each course of TEC was submitted for detection of micrometastases by an immunocytochemical stain (BIS Laboratories, Reseda, CA, USA). Patients who mobilized well (Ͼ5% CD34-positive cells in the circulation) following the first cycle of chemotherapy also mobilized adequately (Ͼ1%) following the second course. Therefore, stem cell collection was deferred to the second course of chemotherapy if mobilization of CD34-positive cells in the circulation exceeded 5% following the first cycle of TEC in the final third group of patients. The aim in all individuals was to re-infuse only those stem cells which had not only been collected after the second cycle of TEC but which had also failed to demonstrate any evidence of micro-metastatic disease. Stem cell collection was performed daily until a target of 5 ϫ 10 6 CD34-positive cells/kg body weight was achieved, if possible.
The CD34-positive cell count was determined from a whole blood specimen prior to leukapheresis and from the leukapheresis product by a method described previously. 4 Mononuclear cells were separated from other cellular elements in the blood through the use of Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). Contaminating red blood cells were lysed by ammonium chloride. The resulting cell suspension was stained with anti-CD34 monoclonal antibody conjugated with fluorescein isothiocyanate (CD34 FITC Anti-HPCA-2) (Becton Dickinson, San Jose, CA, USA). The product underwent flow cytometric analysis on a FACS Calibur (Becton Dickinson) The number of colony-forming units granulocyte-macrophage (CFU-GM) after 14 days of culture of the PBSC product was determined by modification of a previously described method. 5 
Staging evaluation and definitions of response
Sites of disease were determined clinically, with computerized axial tomography (CAT) of the chest and abdomen, and with whole body radionuclide skeletal scintigraphy prior to the initiation of TEC chemotherapy and following the completion of all courses of chemotherapy. A CAT scan of the brain was also performed prior to the initiation of the first cycle of chemotherapy. Complete remission or response (CR) was defined as an absence of measurable disease and normalization of a previously abnormal bone scan. Partial remission or response (PR) was defined as у50% reduction in the size of bidimensionally measurable disease and/or a decrease in intensity or number of lesions seen on bone scan. Any response less than a PR was categorized as no response (NR). Progressive disease (PD) was defined as worsening of disease by clinical examination and/or radiologic evaluation. Chemosensitivity or chemoresistance of metastatic breast cancer was ascertained by its response (CR and PR vs NR and PD) to any standard chemotherapy regimen administered for the treatment of metastatic disease prior to the first cycle of TEC. Standard chemotherapy was defined as any regimen utilized commonly in the management of breast cancer. Toxicity was evaluated according to the World Health Organization guidelines. 6 
Statistical analysis
Several variables were examined as potential determinants of achieving CR after TEC chemotherapy. These included age р or Ͼ than median (45 years), hormone receptor status, response to the most recent standard chemotherapy regimen administered for metastatic disease prior to TEC, intervals from diagnosis of breast cancer and diagnosis of metastases to first cycle of TEC (р of Ͼ than median interval), the number of prior chemotherapy regimens (р1 or Ͼ1), the number of organ systems involved (1 or Ͼ1), prior use of doxorubicin as part adjuvant chemotherapy, presence of visceral disease, and an ECOG performance score of 0 vs 1, 2 or 3. Contingency table ( 2 ) analyses were utilized to estimate the statistical significance of each discrete variable. Continuous variables were compared Bone Marrow Transplantation using the median test. Finally, the joint effect of a combination of variables as a set of 'risk factors' for not achieving a CR following TEC was determined using a logistic regression model.
Results
Patient characteristics
The characteristics of patients enrolled in this study are presented in Table 2 . A total of 100 patients with metastatic breast cancer received 257 courses of TEC. Their median age was 45 years and the median interval from diagnosis of breast cancer to the first cycle of TEC was 30 months. The ECOG performance score was 0 in 58 patients, 1 in 29 patients, 2 in seven patients and 3 in six individuals. Ninety patients had been diagnosed originally with less than stage 4 disease. The interval from diagnosis of breast cancer to the first cycle of TEC was less than 2 years in 77 of these patients, and 2 or more years in 13 individuals. Ten other patients presented with de novo metastatic breast cancer. Seventy-one out of the 90 patients who presented with localized breast cancer were treated with adjuvant chemotherapy, 36 of these with a doxorubicin-containing regimen. Furthermore, 71 of these 90 patients also received a standard chemotherapy regimen once metastatic disease had been identified. The remaining 19 individuals with metastatic disease all of whom had previously received adjuvant chemotherapy were treated either with radiation therapy (n = 8) or surgery (n = 4), or did not receive any treatment following the detection of metastases prior to the first cycle of TEC. Nine out of 10 patients with de novo metastatic disease received at least one standard chemotherapy regimen prior to the first course of TEC. Therefore, all except one patient had already received standard chemotherapy prior to entering this program. Doxorubicincontaining regimens had been administered to 57 patients, taxane-containing regimens to one patient, and both doxorubicin-containing and taxane-containing regimens to 32 patients. Nine individuals received standard chemotherapy regimens which contained neither anthracyclines nor taxanes. Hormonal therapy was administered to a total of 44 patients, in 18 each as part of either adjuvant treatment or treatment of metastatic disease, and in eight individuals as part of both adjuvant therapy as well as treatment for metastatic disease. Thirty-seven of these individuals demonstrated hormone resistance. Two patients were intolerant of hormonal therapy and could not be evaluated for response. Twenty-nine patients received radiation as part of adjuvant therapy, 27 for the treatment of metastatic disease, and 10 patients received radiation as part of both adjuvant therapy as well as for the treatment of metastatic disease. Sites of metastatic disease included the skeletal system (61%), lungs (38%), lymph nodes (32%), liver (31%), skin (27%), pleura (13%), bone marrow (9%), peritoneum (2%) and pericardium (2%). Visceral metastases were noted in 65 patient (57 had liver and/or lung metastases) whereas the skin and/or lymph nodes were the only sites of metastases in 18 individuals. The skeletal system was the only site of involvement in 17 patients. More than one organ system was involved with metastatic disease in most (67%) patients. Micro-metastases were detected in 10 out of 57 patients in whom samples of bone marrow obtained prior to the first cycle of TEC were submitted for immunocytochemical analysis.
Peripheral blood stem cell collection
Four patients failed to mobilize PBSC (р0.1% CD 34-positive cells) and could not undergo stem cell collection following the first cycle of TEC. An additional patient died prior to recovery of her WBC count. In the remaining 95 patients, adequate (у1%) stem cell mobilization was achieved in the peripheral blood on the day of WBC recovery. Leukapheresis was performed in 63 of these 95 patients following the first course of TEC and was deferred to the second cycle of chemotherapy in the remaining 32 patients. The median yield of CD34-positive cells following the first cycle of TEC was 6.2 ϫ 10 6 /kg after a median of one leukapheresis (Table 3) . In 16 patients, fewer than 2 ϫ 10 6 CD34-positive cells/kg could be harvested. The median frequency of CFU-GM was 68.5/10 5 cells. Micro-metastases were detected in four of 54 samples of PBSC submitted for analysis following the first cycle of chemotherapy.
Ninety-three patients received a second course of TEC /kg CD34-positive cells was collected with a median of two leukapheresis procedures. Less than 2 ϫ 10 6 CD34-positive cells/kg could be collected from only two individuals. The median CFU-GM colony count was 61/10 5 cells. Micro-metastases were identified in two of 65 submitted samples.
When the yield of CD34-positive cells collected following both courses of TEC chemotherapy was combined using products which were devoid of micro-metastases, a total of 90 individuals achieved the target of 5 ϫ 10 6 /kg or greater. The remaining nine evaluable patients failed to mobilize an adequate number of PBSC.
Response
One individual suffered early mortality and could not be evaluated for response to TEC. Furthermore, two other patients were also non-evaluable because both entered the program in CR and maintained their remission status following TEC. Therefore, 97 patients were evaluable for response to TEC (Table 4 ). The number of patients who achieved CR or PR following the completion of TEC was 23 (23.7%) and 34 (35.1%), respectively. Nineteen patients (19.6%) had NR and 21 individuals (21.6%) demonstrated PD. Seventy-eight patients underwent subsequent HDC/PBSCT whereas the remaining 21 patients were deemed ineligible (NR or PD, 19 patients, intolerance of chemotherapy, two patients). Eighty patients had received at least one standard chemotherapy regimen for the treatment of metastatic disease prior to referral to our program. Seventy-one patients began TEC immediately after the completion of a standard chemotherapy regimen. Disease status in these 71 patients prior to the initiation of TEC was CR in two patients, PR in 31 patients, NR in 15 patients and PD in 23 patients. Nine other patients received their last cycle of standard chemotherapy more than 6 months prior to the first course of TEC. The status of their disease upon completion of their last standard chemotherapy regimen was CR in one patient, PR in five patients, NR in one patient and PD in two patients. All of these nine individuals developed PD before their first cycle of TEC. Therefore, in the entire group of 80 patients who had received at least one standard chemotherapy regimen for the treatment of metastatic disease, 41 (16 patients with NR and 25 patients with PD) had failed to respond to the latest regimen (chemoresistant group) whereas 39 patients (three CR and (Table 5 ). In the group of 20 patients who did not receive any standard chemotherapy for the treatment of metastatic disease, six individuals achieved a CR including the solitary patient who had not received any standard chemotherapy (adjuvant or for metastases) prior to TEC. A number of variables was investigated in an attempt to predict which patients would enter CR at the completion of TEC chemotherapy (Table 5 ). Univariate analysis identified four significant variables for a patient to achieve CR. These included previously documented chemosensitivity (P Ͻ 0.001), involvement of only one organ system (P ϭ 0.002), an ECOG performance score of 0 (P Ͻ 0.001) and a short interval (р8 months) from diagnosis of metastatic disease to first course of TEC (P ϭ 0.038). Response was also analyzed using a logistic regression model. Candidate predictors included interval from diagnosis of metastatic disease to first cycle of TEC, number of organ systems involved, ECOG performance score and chemosensitivity of the tumor. The final model included the number of organ systems involved, ECOG performance score and chemosensitivity terms. Involvement of two or more organ systems increased the chances of less than a CR by 7.2-fold. Chemosensitivity reduced the chances of less than a CR by nearly 92.6%. The correct classification rate for this model was 84.8%.
The median time to engraftment in the 78 patients who underwent HDC-PBSCT was day +9 (range +7 to +12) following stem cell infusion. The median duration of neutropenia was 7 days (range 4 to 11 days). An unsupported platelet count of 20 ϫ 10 9 /l was observed on the same day as neutrophil recovery. The disease status of these 78 Table 5 Variables associated with complete response after TEC 
Toxicity
A total of 61 (23.7%) febrile episodes were observed following 257 courses of TEC. These patients required readmission to the hospital as well as initiation of broadspectrum antibiotic therapy. Bacteremia was documented in only 10 instances (4%). Organisms causing bacteremia included Streptococcus viridans (n = 3), Staphylococcus epidermidis (n = 2), Eschericia coli (n = 1), Proteus mirabilis (n = 1), Xanthamonas maltophilia (n = 1), Acinetobacter species (n = 1), and Staphylococcus aureus (n = 1). Three episodes of fungemia with Candida tropicalis were also observed. One patient died from hemodynamic collapse during neutropenic fever following the first cycle of TEC. However, no organisms could be isolated from this patient and permission for autopsy was not granted. There were eight other readmissions for either vomiting, dehydration or catheter-related thrombosis. The total number of patients readmitted was 50. The median duration of readmission following TEC was 1.5 days yielding a total of 4.5 days of hospitalization (3 additional days for administration of chemotherapy). The incidence of grade 4 leukopenia was 100%. In fact, a total WBC count of Ͻ0.1 ϫ 10 9 /l was noted after every cycle of TEC chemotherapy. The median interval from initiation of chemotherapy to recovery of ANC Ͼ1 ϫ 10 9 /l was 14 days. The median duration of neutropenia was 6 days. Grade 3 thrombocytopenia was seen following 38 cycles (14.8%) of chemotherapy whereas grade 4 toxicity was observed during the remaining courses. There was not a single instance of grade 4 anemia. The median number of platelet products transfused per course of chemotherapy was one. The median number of PRBC transfusions per cycle of chemotherapy was also one. Red cell transfusions were not required during 101 cycles of TEC chemotherapy (Table 6) .
Grade 3 alopecia was noted in all evaluable patients. Grade 3 stomatitis, nausea and vomiting, and diarrhea were seen during 26, 40 and 56 courses of chemotherapy, respectively. Only one patient developed hyperbilirubinemia during the course of neutropenic fever, which resulted in mortality. There were 62 instances of grade 1 peripheral neuropathy. Mortality rate as a direct consequence of TEC was 1% per patient and 0.4% per cycle of chemotherapy. 
Discussion
The concentration of stem cells in the peripheral blood is only 1-10% that in the bone marrow. 7 However, the number of circulating stem cells as determined by assays for CFU-GM, blood mononuclear cells or CD34-stained cells increases up to 20-fold during recovery from pancytopenia following myelosuppresive chemotherapy. 8, 9 Numerous strategies have been devised to increase the number of PBSC. [10] [11] [12] [13] [14] Chemotherapy alone was utilized initially for PBSC mobilization. The doses of chemotherapy administered for this purpose have been intense and have resulted in severe myelosuppression. The most commonly utilized agent has been cyclophosphamide (4-7 g/m 2 i.v.) which has yielded a 5-to 30-fold increase in the number of CD34-positive cells or CFU-GM in the circulation at a median of 14-16 days following chemotherapy. [15] [16] [17] The use of combination chemotherapy as opposed to single agent chemotherapy enhances stem cell mobilization. 18 The addition of paclitaxel or etoposide to cyclophosphamide has yielded better results than cyclophosphamide alone. 19 The emergence of colony-stimulating factors (CSF) for clinical use has also been associated with improved stem cell mobilization. The use of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a single agent increases circulating CFU-GM by 8.5-to 18-fold. 20, 21 Similarly, G-CSF alone enhances the number of circulating CFU-GM 58-fold. 22 A comparison of G-CSF and GM-CSF demonstrated better results with G-CSF as a single agent. 23 The addition of a CSF to cyclophosphamide results in a 62.5-to 159-fold increase in the number of circulating CFU-GM compared to a 30-fold elevation with cyclophosphamide alone. 17, 20, 24 Furthermore, CSFs shorten the median time to reach peak values of PBSC following chemotherapy. 25 Additionally, it has been suggested that the use of CSF alone may fail to recruit the most primitive hematopoietic progenitors. 26 Therefore, a combination of multi-agent chemotherapy and CSF appears to be most effective in mobilizing PBSC. Frequently used chemotherapeutic agents include cyclophosphamide, etoposide, paclitaxel, ara-C, ifosfamide, cisplatin and anthracyclines. 18, 19, 25, [27] [28] [29] [30] [31] In this study, we combined cyclophophamide with paclitaxel and etoposide because all three are excellent stem cell mobilizing agents. Granulocyte colony-stimulating factor was administered daily following the completion of chemotherapy until recovery of the WBC count and/or collection of PBSC.
Either CFU-GM assays or peripheral blood CD34-positive cell counts can be used to ascertain the adequacy of stem cell collection. CD34-positive cell counts are being utilized increasingly because their assessment can be performed rapidly and the results are readily reproducible. A minimum of 0.5-2.0 ϫ 10 6 CD34-positive cells/kg has been postulated as necessary for subsequent hematopoietic reconstitution. 32, 33 Furthermore, faster recovery of counts is not observed after PBSCT if Ͼ8 ϫ 10 6 CD34-positive cells/kg are infused vs 5-8 ϫ 10 6 cells/kg. 13 Risk factors for poor stem cell mobilization include bone marrow involvement by malignancy, a slow rise of the WBC count following chemotherapy, numerous prior chemotherapy cycles and regimens, an interval of less than 50 days from the most recent chemotherapy, prior use of radiation therapy, increasing age, stem cell mobilization with chemotherapy alone, diagnosis other than breast cancer especially acute myelogenous leukemia, metastatic breast cancer as opposed to locally advanced breast cancer, platelet count Ͻ150 ϫ 10 9 /l, and prior use of melphalan, BCNU or mitomycin-C. 16, 25, 29, 31, 32, 34, 35 Ninety percent of our patients mobilized a sufficient number of PBSC despite the co-existence of numerous risk factors for poor mobilization described above. The characteristics of those nine patients who failed to mobilize the targeted number of PBSC are outlined in Table 7 . As is evident, these characteristics were not significantly different from the entire patient population (Table 2) .
Peripheral blood stem cell harvesting has been performed successfully following disease-oriented chemotherapy with CSF support. 31, 36, 37 However, it has also been demonstrated that an increase in dose intensity is associated with improved stem cell mobilization and yield. 31 We chose a regimen in which all three chemotherapeutic agents were active against breast cancer and two (paclitaxel and cyclophosphamide) were moderately to highly active. 38 The rationale was to utilize this dose-intense regimen not just for stem cell mobilization but also as disease-oriented therapy. Furthermore, several cycles of chemotherapy were administered to achieve maximal tumor cytoreduction prior to HDC/PBSCT. Additionally, whenever possible, only stem cells collected following the second cycle of TEC were used for transplantation in order to reduce the possibility of tumor cell contamination of harvested PBSC.
Patients already in CR at the time of HDC/PBSCT are the ones most likely to have prolonged progression-free survival following PBSCT. 3 The probability of achieving a CR with first-line conventional chemotherapy for newly Table 7 Characteristics of patients who did not mobilize stem cells adequately diagnosed metastatic breast cancer is 15% (range 5-25%). 38 However, the chances of obtaining a CR are reduced by half with each subsequent disease progression. 38 Almost all of our patients had already received one or two prior chemotherapy regimens. Therefore, the CR rate of 23.7% achieved with TEC in this group of patients compares favorably with the results obtained with standard second-line chemotherapy regimens utilized in the treatment of metastatic breast cancer. Responsiveness to prior standard chemotherapy, an ECOG performance score of 0 and involvement by disease of only a single organ system was associated with a higher probability of attaining a CR after TEC.
In conclusion, we report a novel, dose-intense combination of paclitaxel, etoposide and cyclophosphamide supported by G-CSF which was utilized not just for stem cell mobilization but also for optimal tumor cytoreduction prior to HDC/PBSCT. The regimen was safe and well-tolerated with a mortality rate of 1%. However, patients had to be followed closely during pancytopenia because of grade 4 leukopenia and thrombocytopenia. Although the current study did not compare TEC to standard disease-oriented chemotherapy in metastatic breast cancer, the CR rate of over 23% in this population of heavily pre-treated patients was quite encouraging. The regimen was also effective in mobilizing PBSC in the vast majority of individuals. Finally, such a regimen could be utilized in the future to select patients with metastatic breast cancer most likely to benefit from HDC/PBSCT such as those with a limited amount of chemosensitive disease who respond completely to TEC. Furthermore, HDC/PBSCT induced only one additional CR beyond those achieved with TEC and failed to maintain TEC-induced complete remissions in seven of 24 patients. Therefore, it will also be interesting to ascertain whether a dose-intense regimen such as TEC could obviate the need for HDC/PBSCT and its attendant complications in patients with metastatic breast cancer.
